Early Management Strategies of Acute Heart Failure for Patients With NSTEMI

• Status: Enrolling by invitation
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

There are always poor outcomes in patients with acute myocardial infarction(AMI) combined with elevated BNP/NT-proBNP level. An elevated BNP/NT-proBNP level highly indicates acute heart failure(AHF).Levosimendan is recommended in many clinical trials of heart failure and Chinese heart failure guidelines. As a result, the investigators form a hypothesis that when patients with AMI combined with elevated BNP/NT-proBNP level are in conditions before AHF, to use levosimendan may reduces the risk of heart failure and improve the outcome.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Qilu Hospital of Shandong University
• Treatments: Simendan

Criteria

Inclusion Criteria:

1. Patients diagnosed with NSTEMI in outpatient service or admitted to hospital;

2. Patients with an elevated NT-proBNP level;

3. Patients sign the informed consent;

Exclusion Criteria:

1. Patients with hypotension(systolic pressure<100mmHg), creatinine clearance rate<30ml/min or be allergic to levosimendan;

2. Patients whose heart function grade of Killip are Level III~IV;

3. Patients suffering from hepatic failure, renal failure or other diseases which may shorten the lifetime to 6 months(for example tumor);

4. Patients with valvular heart diseases influencing haemodynamics, hypertrophic or restricted cardiomyopathy, constrictive pericarditis, severe pulmonary hypertension or myocarditis;

5. Patients with serum potassium level<3.5mmol/L;

6. Pregnant and lactating women;

7. Patients participating in other relevant clinical studies.